GKOS Glaukos Corporation
USHealthcareAs of 2026-08-24
Why GKOS matters now
Glaukos Corporation (GKOS) is a US stock in Healthcare. The latest InvestLog snapshot shows $185.75 with +0.46% on the session and $10.96B in market capitalization; recent performance reads 1-month -6.59% and YTD +15.74%.
The latest financial table shown here is Q1 2026, with revenue of $150.6M, net income of $-19.8M, and EPS of $-0.34. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -0.2%.
InvestLog's latest related AI research is a Insider Sale note titled "Gilliam Joseph E sells $10.8M of GKOS". The latest indexable market news headline is "61,957 Shares in Glaukos Corporation GKOS Purchased by Deutsche Bank AG" from Defense World.
Additional event context on this page matters because analyst consensus is Buy with a median target of $147.50; recent insider activity includes Navratil Tomas filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
11.30
P/S
13.92
EV/EBITDA
-53.29
DCF Value
$-79.00
FCF Yield
-0.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
78.1%
Operating Margin
-15.6%
Net Margin
-34.3%
ROE
-26.5%
ROA
-21.2%
ROIC
-10.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $150.6M | $-19.8M | $-0.34 |
| Q4 2025 | $143.1M | $-133.7M | $-2.32 |
| FY 2025 | $507.4M | $-187.7M | $-3.28 |
| Q3 2025 | $133.5M | $-16.2M | $-0.28 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$151.25
Target (Median)
$147.50
Target Range
$135.00 - $170.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
0.81
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.